

A Threat to Abortion Pills. Plus, the U.S. Shares Secrets
27 snips Mar 1, 2023
Pam Belluck, a health and science correspondent for The New York Times, discusses the looming legal battle over the abortion pill mifepristone, highlighting its significance for reproductive rights. Julian E. Barnes, a national security correspondent, sheds light on the Biden administration's unprecedented disclosure of intelligence regarding China's potential military support for Russia. Their conversation probes the implications of these issues on both domestic health policies and international diplomacy.
AI Snips
Chapters
Transcript
Episode notes
Lawsuit Challenges Mifepristone Approval
- Anti-abortion groups sue FDA, challenging mifepristone's approval for medication abortions.
- They argue its approval was procedurally flawed and the drug is unsafe, risking hemorrhaging and infections.
Strategic Venue Choice
- The lawsuit was filed in Amarillo, Texas, where a single, conservative judge presides.
- This suggests a strategic choice of venue to increase the likelihood of a favorable ruling.
Broader Implications
- A ruling against the FDA could have broad implications, setting a precedent for revoking other drug approvals.
- This could affect vaccines, contraception, and other medications.